Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: Study of their clinical significance

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 595-600

  Murakami, Hidetsugu ^a   Ogata, Yutaka ^a,b   Akagi, Yoshito ^a   Ishibashi, Nobuya ^a   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Anti angiogenesis; Circulating endothelial cell; Irinotecan; Maximum tolerated dose; Surrogate marker for angiogenesis

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN;

EID: 79958054297     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.253     Document Type: Article

References (31)

1. Eskens FA: Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 90: 1-7, 2004.
2. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
3. Warren RS, Yuan H, Matli MR, et al: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789-1797, 1995
4. Takahashi Y, Ellis LM and Mai M: The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion. Oncol Rep 10: 9-13, 2003.
5. Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967, 1997
6. Asahara T, Takahashi T, Masuda H, et al: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972, 1999
7. Bocci G, Francia G, Man S, et al: Thrombospondin 1, a mediator of the anti-angiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100: 12917-12922, 2003.
8. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436, 2004
9. Monestiroli S, Mancuso P, Burlini A, et al: Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 61: 4341-4344, 2001.
10. Bocci G, Nicolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002.
11. Shaked Y, Emmenegger U, Man S, et al: Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum anti-angiogenic activity. Blood 106: 3058-3061, 2005
12. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study group. J Clin Oncol 11: 909-913, 1993.
13. Rothenberg ML, Cox JV, deVore RF, et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85: 786-795, 1999
14. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
15. Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination wit-cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005
16. Beaudry P, Force J, Naumov G, et al: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of anti-angiogenic activity. Clin Cancer Res 11: 3514-3522, 2005
17. Nitta K, Yokokura T, Sawada S, et al: Antitumor activity o: novel derivatives of camptothecin. Jpn J Cancer Chemother 14 850-857, 1987
18. Bertolini F, Paul S, Mancuso P, et al: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346, 2003.
19. Capillo M, Mancuso P, Gobbi A, et al: Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9: 377-382, 2003.
20. Mizobe T, Ogata Y, Murakami H, et al: Effcacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep 20: 517-523, 2008
21. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24, 2000.
22. Browder T, Butterfeld CE, Kräling BM, et al: Anti-angiogenic scheduling of chemotherapy improves effcacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
23. Colleoni M, Rocca A, Sandri MT, et at. Low-dose oral metho-trexate and cyclophosphamide in me:astatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13: 73-80, 2002.
24. + hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodefcient mouse model of human non-Hodgkin's lymphoma. Cancer Res 61: 7654-7659, 2001.
25. Schuch G, Heymach JV, Nomi M, et al: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63: 8345-8350, 2003.
26. Twelves C; Xeloda Colorectal Cancer group: Capecitabine as frst-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38 (Suppl. 2): S15-S20, 2002.
27. Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and peroral leucovorin versus fuorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-3616, 2002.
28. Santini D, Vincenzi B, Schiavon G, et al: Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol 59: 613-620, 2007
29. Goto A, Yamada Y, Yasui H, et al: Phase II study of combina-tion therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 6: 968-973, 2006.
30. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004
31. Ogata Y, Sasatomi T, Mori S, et al: Signifcance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifuridine for advanced colorectal carcinoma. Anticancer Res 27: 2605-2612, 2007